A Phase 1b Study With Volociximab in Combination With Carboplatin and Paclitaxel in First-line, Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 1 Completed 33 enrolled AbbVie

NaSingle-groupOpen-labelTreatment

Summary

The primary purpose of this study is to examine the safety of volociximab in combination with a standard treatment of carboplatin and paclitaxel in subjects previously untreated with chemotherapy for advanced stage (IIIB/IV) non-small cell lung cancer (NSCLC).

Timeline

Start: 2007-12
Primary completion: 2010-05
Completion: 2010-05

Publications

Results Besse B, Tsao LC, Chao DT, Fang Y, Soria JC, Almokadem S, Belani CP. Phase Ib safety and pharmacokinetic study of volociximab, an anti-alpha5beta1 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer. Ann Oncol. 2013 Jan;24(1):90-6. doi: 10.1093/annonc/mds281. Epub 2012 Aug 16.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Volociximab	Monoclonal antibody	10 mg/kg	Intravenous
Subject	Volociximab	Monoclonal antibody	15 mg/kg	Intravenous
Subject	Volociximab	Monoclonal antibody	20 mg/kg	Intravenous
Subject	Volociximab	Monoclonal antibody	30 mg/kg	Intravenous
Background	Carboplatin	Small molecule	—	Intravenous
Background	Paclitaxel	Small molecule	200 mg/m2	Intravenous

A Phase 1b Study With Volociximab in Combination With Carboplatin and Paclitaxel in First-line, Advanced Non-Small Cell Lung Cancer (NSCLC)

Summary

Timeline

Publications

Drugs

Indications